ORMP Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Oramed Pharmaceuticals Inc. had $2.0M of revenue in fiscal 2025. Over five years, revenue changed β5.9% a year on average.
Last close Β· Oct 23, 2026
$4.13
0.2%Hi! I read Oramed Pharmaceuticals Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Does it make a profit?
3,202.5%
Yes. It keeps 3,202.5% of every sale as profit.
Does profit turn into cash?
β457.7%
No. It spent more cash than it brought in.
How is the share priced?
1.0x
One share costs 1.0 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Oramed Pharmaceuticals Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 12, 2026
Thursday Β· in 18 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 10, 2026 | Q2 '26 | After the market closes | 10-Q β |
| May 19, 2026 | Q1 '26 | After the market closes | 10-Q β |
| Mar 26, 2026 | Q4 '25 | After the market closes | 10-K β |
| Oct 20, 2025 | Q3 '25 | Time not announced | 8-K β |
| Aug 14, 2025 | Q2 '25 | After the market closes | 10-Q β |
| May 15, 2025 | Q1 '25 | After the market closes | 10-Q β |
| Mar 27, 2025 | Q4 '24 | After the market closes | 10-K β |
| Nov 7, 2024 | Q3 '24 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Oramed Pharmaceuticals Inc. had $2.0M of revenue in fiscal 2025. Over five years, revenue changed β5.9% a year on average. Its operating margin was β754.4%: of every 100 in sales, about β754 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Oramed Pharmaceuticals Inc. made $64.1M of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew 6.2% a year.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$9.2M in fiscal 2025, β457.7% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Oramed Pharmaceuticals Inc. returned $4.7M to shareholders in fiscal 2025. The diluted share count rose 3.8%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Oramed Pharmaceuticals Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $83.1M | $44.2M | $66.8M | $57.9M | $51.4M |
| Debt incl. finance leases | $12.5M | $0.0M | $51.0M | β | β |
| Debt / equity | 0.1x | 0.0x | 0.3x | β | β |
| Interest coverage | β | β | β7.7x | β15.0x | β |
| Current ratio | 14.3x | 27.3x | 3.1x | 25.2x | 7.0x |
| Quick ratio | 14.3x | 27.3x | 3.1x | 25.2x | 7.0x |
| Total assets | $128M | $162M | $221M | $155M | $231M |
| Total liabilities | $12.2M | $9.8M | $56.7M | $9.0M | $31.1M |
| Shareholders' equity | $116M | $152M | $164M | $146M | $200M |
| Net debt (β = net cash) | β$70.6M | β$44.2M | β$15.8M | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 3 / 8 | 2 / 9 | 2 / 7 | 3 / 7 | β / 2 | β / 5 | β / 6 | β / 6 |
| Accruals ratio | β36.5% | β11.4% | 4.5% | β3.4% | 2.3% | β2.1% | β | 8.0% | β5.7% | 37.9% |
| Altman Z'' | 0.81 | β3.03 | β1.01 | β3.83 | β0.31 | 10.29 | β | 3.48 | 18.59 | 7.80 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.6M | $2.5M | $2.4M | $2.7M | $2.7M | $2.7M | β | $1.3M | β | $2.0M |
| Gross profit | $0.2M | $2.3M | $2.5M | $2.6M | β | β | β | β | β | $0.0M |
| Research and development | $7.7M | $10.3M | $12.0M | $13.5M | $10.2M | $21.0M | β | $9.0M | $6.3M | $6.4M |
| Operating income | β$10.0M | β$10.8M | β$13.5M | β$14.6M | β$11.8M | β$24.2M | β | β$15.8M | β$12.8M | β$15.1M |
| Interest expense | β | β | β | β | β | β | β | $2.0M | $0.9M | β |
| Pretax income | β$9.6M | β$10.1M | β$12.7M | β$14.1M | β$11.5M | $5.3M | β | $5.1M | β$15.9M | $75.3M |
| Income tax | $1.3M | $0.4M | β | $0.3M | β | β | β | β | $3.2M | $11.3M |
| Net income | β$11.0M | β$10.5M | β$12.7M | β$14.4M | β$11.5M | β$23.0M | β | $5.1M | β$19.1M | $64.1M |
| Net income to common | β | β | β | β | $11.5M | $23.0M | β | β | β$19.1M | $63.2M |
| Diluted EPS | $0.87 | $0.79 | $0.86 | $0.82 | $0.56 | $0.78 | β | $0.14 | β$0.48 | $1.50 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.02B | 0.02B | 0.03B | β | 0.04B | 0.04B | 0.04B |
| Cash flow | ||||||||||
| Cash from operations | $4.7M | β$5.8M | β$14.7M | β$12.9M | β$12.4M | β$21.2M | β | β$10.3M | β$8.4M | β$9.1M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.4M | β | $0.3M | $0.0M | $0.0M |
| Free cash flow | $4.6M | β$5.8M | β$14.7M | β$13.0M | β$12.5M | β$21.6M | β | β$10.5M | β$8.4M | β$9.2M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | β | $0.2M | $0.2M | $0.1M |
| Stock-based compensation | $0.6M | $1.6M | $1.5M | $0.8M | $0.5M | $2.7M | β | $4.2M | $4.1M | $6.0M |
| Share buybacks | β | β | β | β | β | β | β | β | $2.5M | $4.7M |
| Dividends and buybacks | β | β | β | β | β | β | β | β | $2.5M | $4.7M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $6.8M | $6.8M | $9.6M | $7.0M | $22.6M | $83.1M | $44.2M | $66.8M | $57.9M | $51.4M |
| Total debt | β | β | $13.8M | $12.4M | β | $12.5M | $0.0M | $51.0M | β | β |
| Deposits | β$11.0M | β | β | β | β | β | β | β | β | β |
| Current assets | $31.2M | $20.3M | $31.0M | $33.3M | $40.5M | $95.3M | $157M | $163M | $143M | $133M |
| Current liabilities | $3.6M | $5.2M | $4.6M | $5.3M | $4.5M | $6.7M | $5.7M | $53.2M | $5.7M | $19.1M |
| Property and equipment, net | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.4M | $0.8M | $0.9M | $0.7M | $0.6M |
| Total assets | $42.8M | $38.7M | $47.4M | $34.7M | $44.6M | $128M | $162M | $221M | $155M | $231M |
| Total liabilities | $16.6M | $19.5M | $16.3M | $15.3M | $11.8M | $12.2M | $9.8M | $56.7M | $9.0M | $31.1M |
| Shareholders' equity | $26.2M | $19.2M | $31.1M | $19.4M | $32.9M | $116M | $152M | $164M | $146M | $200M |
| Margins | ||||||||||
| Gross margin | 23.6% | 92.4% | 103.5% | 96.7% | β | β | β | β | β | 0.7% |
| Operating margin | β1,561.6% | β438.6% | β552.3% | β541.3% | β433.8% | β896.2% | β | β1,176.8% | β | β754.4% |
| EBITDA margin | β1,561.0% | β438.4% | β552.1% | β541.0% | β433.6% | β893.3% | β | β1,162.2% | β | β748.4% |
| Net margin | β1,710.5% | β426.7% | β519.7% | β531.1% | β424.8% | β850.5% | β | 379.7% | β | 3,202.5% |
| FCF margin | 724.8% | β237.7% | β598.7% | β479.3% | β462.1% | β797.5% | β | β787.2% | β | β457.7% |
| Returns | ||||||||||
| Return on capital | β | β | β30.2% | β46.8% | β | β42.3% | β | β8.4% | β | β |
| Return on capital employed | β25.5% | β32.1% | β31.6% | β49.8% | β29.3% | β20.0% | β | β9.4% | β8.5% | β7.1% |
| Return on equity | β41.9% | β46.1% | β50.6% | β56.8% | β44.0% | β30.9% | β | 3.2% | β12.3% | 37.0% |
| Return on assets | β25.6% | β25.7% | β29.6% | β35.0% | β29.0% | β26.6% | β | 2.7% | β10.1% | 33.2% |
| Return on tangible equity | β41.9% | β54.5% | β40.9% | β74.0% | 35.0% | 19.9% | β | 3.1% | β13.0% | 31.7% |
| Growth | ||||||||||
| Revenue growth | β | 283.2% | β0.3% | 10.4% | 0.3% | β0.3% | β | β | β | β |
| Net income growth | β | β | β | β | β | β | β | β | β474.6% | β |
| EPS growth | β | β9.2% | 8.9% | β4.7% | β31.7% | 39.3% | β | β | β442.9% | β |
| FCF growth | β | β225.7% | β | β | β | β | β | β | β | β |
| Share count change | β | 5.4% | 11.8% | 17.3% | 17.6% | 38.7% | β | β | 0.7% | 3.8% |
| Financial health | ||||||||||
| Debt / equity | β | β | 0.4x | 0.6x | β | 0.1x | 0.0x | 0.3x | β | β |
| Interest coverage | β | β | β | β | β | β | β | β7.7x | β15.0x | β |
| Current ratio | 8.6x | 3.9x | 6.8x | 6.3x | 8.9x | 14.3x | 27.3x | 3.1x | 25.2x | 7.0x |
| Quick ratio | 8.6x | 3.9x | 6.8x | 6.3x | 8.9x | 14.3x | 27.3x | 3.1x | 25.2x | 7.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.4% | 0.3% | 0.2% | 0.6% | 3.0% | 13.9% | β | 19.0% | β | 0.5% |
| Stock comp / revenue | 98.9% | 64.1% | 63.2% | 29.9% | 17.2% | 99.7% | β | 314.3% | β | 299.6% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 3.0 | 2.0 | 2.0 | 3.0 | β | β | β | β |
| Altman Z'' | 0.8 | β3.0 | β1.0 | β3.8 | β0.3 | 10.3 | β | 3.5 | 18.6 | 7.8 |
| Accruals ratio | β36.5% | β11.4% | 4.5% | β3.4% | 2.3% | β2.1% | β | 8.0% | β5.7% | 37.9% |
Source: SEC EDGAR XBRL filings (CIK 0001176309). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
